


1a



1b




1c




(continued on next page)

(continued from previous page)

1d



1e



1f





FIG. 1

2a


Competitive binding against 10 nM biotinylated PR000400
MFI
12,000
10,000
8,000
6,000
4,000
2,000
0
0.1
1
10
100
1000
Antibody concentration (nM)
PR004533
PR004536
PR004540
PR004227
PR004949
PR004950
PR004952
PR004953
PR000400
PR004549
ISO hIgG1

2b




Competitive binding against 200 nM biotinylated PR004549
MFI
5,000
4,000
3,000
2,000
1,000
0
0.1
1
10
100
1000
Antibody concentration (nM)
PR004533
PR004536
PR004540
PR004227
PR004949
PR004950
PR004952
PR004953
PR000400
PR004549
ISO hIgG1

FIG. 2

3a


NUGC4_D8
150
100
50
0
Cell viability (%)
0.01
0.1
1
10
100
1000
Antibody concentration (nM)
PR000400
PR007247

3b





NUGC4_D8
150
100
50
0
Cell viability (%)
0.01
0.1
1
10
100
1000
Antibody concentration (nM)
PR000400
PR007244
PR007245
PR007246
PR007248

FIG. 3

4a



4b





(continued on next page)

(continued from previous page)

4c


Structure (3) HCAb_LC-Fab






4d

Structure (4) VH-VH_HC-Fab







(continued on next page)

(continued from previous page)

4e


Structure (5) **VH-VH_LC-Fab**






4f

Structure (6) **VH_HC-Fab-Fc-Dual VH**






(continued on next page)

(continued from previous page)

4g



4h






FIG. 4


5a



5b




5c




(continued on next page)

(continued from previous page)


5d



5e




5f




(continued on next page)

(continued from previous page)


5g



5h




5i




(continued on next page)

(continued from previous page)


5j



5k




5l




(continued on next page)

(continued from previous page)


5m



5n




5o




(continued on next page)

(continued from previous page)


5p



5q



5r



(continued on next page)

(continued from previous page)

5s






FIG. 5

6a




6b




(continued on next page)

(continued from previous page)

6c




6d




(continued on next page)

(continued from previous page)

6e




6f




(continued on next page)

(continued from previous page)

6g




6h




(continued on next page)

(continued from previous page)

6i




6j




(continued on next page)

(continued from previous page)

6k




6l




(continued on next page)

(continued from previous page)

6m




6n




(continued on next page)

(continued from previous page)

6o




6p




(continued on next page)

(continued from previous page)

6q




6r




(continued on next page)

(continued from previous page)

6s




6t




(continued on next page)

(continued from previous page)

6u



6v



(continued on next page)

(continued from previous page)

6w




FIG. 6





PR004549
PR006384
PR006292
Positive Control
hCLDN1
hCLDN2
hCLDN3
hCLDN4
hCLDN6
hCLDN9

FIG. 7

8a


HEK293/cynoCLDN18.1
Median fluorescence intensity (A.U.)
30,000
20,000
10,000
0
0.1
1
10
100
1000
Antibody concentration (nM)
Iso hIgG1
PR004549
PR006384
PR005411
PR006292
PR000400
PR002725

8b


HEK293/cynoCLDN18.2
Mean fluorescence intensity (A.U.)
1,000,000
800,000
600,000
400,000
200,000
0
0.1
1
10
100
1000
Antibody concentration (nM)
Iso hIgG1
PR004549
PR006384
PR005411
PR006292
PR000400

8c



Cynomolgus CD3+ cells
Median fluorescence intensity (A.U.)
200
150
100
0.1
1
10
100
1000
Antibody concentration (nM)
Iso hIgG1
PR006292

FIG. 8




HEK293/cynoCLDN18.2
TDCC (%)
20
15
10
5
0
0.1
1
10
100
1000
10000
100000
PR006292
Antibody concentration (pM)

FIG. 9

10a



10b





FIG. 10

11a



11b





FIG. 11

12a



12b





FIG. 12

13a



13b




FIG. 13





Balb/c nude mice, 5 mg/kg, intravenous infusion
Antibody concentration (μg/mL)
1000
100
10
1
0
2
4
6
8
10
12
14
16
Time (day)
PR006292, total assay
PR006292, domain assay
PR006384, total assay
PR006384, domain assay
PR004549, total assay
PR004549, domain assay

FIG. 14

15a




15b




(continued on next page)

(continued from previous page)

15c



15d



(continued on next page)

(continued from previous page)

15e




FIG. 15